Minimally Invasive Esophagectomy in Semi-Prone Position (Pawar Technique): Technical Aspects and Outcome in 224 Patients.

Background and Objectives There are two patient positions described for minimally invasive esophagectomy (MIE) for esophageal cancer, viz., left lateral and prone positions. To retain the benefits and overcome the disadvantages of these positions, a semi-prone position was developed by us. Our objective was to analyze the feasibility of performing MIE in this position. Materials and Methods A retrospective review of patients who underwent MIE at our center from January 2007 to December 2017 was done. A semi-prone position is a left lateral position with an anterior inclination of 45 degrees. Intraoperative parameters including conversion rate, immediate postoperative outcomes, and long-term oncological outcomes were analyzed. Statistical Analysis Statistical Package for the Social Sciences version 19 (IBM SPSS, IBM Corp., Armonk, New York, United States) was utilized for analysis. Survival analysis was done using Kaplan-Meier graph. Quantitative data were described as mean or median with standard deviation, and qualitative data were described as frequency distribution tables. Results Consecutive 224 patients with good performance status were included. After excluding those who required conversion (14 [6.6%]), 210 patients were further analyzed. Median age was 60 years (range: 27-80 years). Neoadjuvant treatment recipients were 160 (76%) patients. Most common presentation was squamous cell carcinoma (146 [70%]) of lower third esophagus (140 [67%]) of stage III (126 [60%]). Median blood loss for thoracoscopic dissection and for total operation was 101.5 mL (range: 30-180 mL) and 286 mL (range: 93-480 mL), respectively. Median operative time for thoracoscopic dissection alone was 67 minutes (range: 34-98 minutes) and for entire procedure was 215 minutes (range: 162-268 minutes). There was no intraoperative mortality. Median 16 lymph nodes were dissected (range: 5-32). Postoperative complication rate and mortality was 50% and 3.3%, respectively. Disease-free interval was 18 months (range: 3-108 months) and overall survival was 22 months (range: 6-108 months). Conclusion MIE with mediastinal lymphadenectomy in a semi-prone position is feasible, convenient, oncologically safe, which can combine the benefits of the two conventional approaches. Further prospective and comparative studies are required to support our findings.

Preoperative Chemoradiation in Locally-Advanced Resectable Carcinoma of the Esophagus in a Single Rural Cancer Hospital in Western India.

Background The current standard of care for the treatment of surgically resectable carcinoma of the esophagus is preoperative chemoradiation followed by surgery. There is strong evidence that this trimodality approach improves survival as compared with surgery alone. Objective The objective of this study is to determine the feasibility of this approach in a rural cancer institute in western India. Materials and Methods The data of all the 157 consecutively treated patients with locally-advanced carcinoma of the esophagus from March 2013 to March 2017 who were started on preoperative chemoradiation were analyzed retrospectively. Results Of the 157 patients who were started on preoperative chemoradiation, 68 patients underwent surgery. There are various practical reasons for not undergoing the definitive surgery, with the important being the socioeconomic support to the patients during the course of treatment. Conclusion This study gave us insight into the strategic selection of patients for the trimodality approach as well as the need for continuous socioeconomic support throughout the treatment course.

Brain metastasis from nonnasopharyngeal head and neck squamous cell carcinoma: A case series and review of literature.

BACKGROUND: Brain metastasis from primary head and neck squamous cell carcinoma (HNSCC) is infrequent and probably under-reported thereby leading to paucity of information. METHODS: Archives of two institutes in India were studied from 2005 to 2013 and relevant information regarding patient demographics, treatment details, and follow-up was obtained for patients having brain metastasis (BM) from HNSCC. Data were analyzed using SPSS software version 20 (IBM Corporation, NY, USA). RESULTS: Metastasis to the brain was detected in 17 patients with an HNSCC primary. The median age for diagnosis of index primary was 55 years (range (R) - 32-71 years) with 88% (15/17) being male. Oral cavity was the most common site of primary disease with 35% (6/17) followed by larynx (24%), oropharynx (18%), and hypopharynx (18%). The median stage at presentation was IVA (47%) and two (12%) were metastatic to the brain at presentation. Human papillomavirus analysis was not available for any of the patients. Neurological symptoms were complained of in 94% patients. The median BM-free-interval was 15 months (R - 1-67 months, SE ± 5.2). While 88% had multiple brain metastases, 82% also had extracranial metastasis and in 53% of patients, the index primary was not controlled. The median overall survival of all patients after the development of BM was 2 months (R - 0.5-6 months, SE ± 0.4). CONCLUSION: BM in HNSCC is mostly multiple, associated with extracranial metastasis and can occur in patients without locoregional relapse or residual disease and carries a dismal outcome.

A rare case of multicentric carcinoma left breast synchronous with carcinoma right lung: Therapeutic challenge in radiotherapy.

Multiple primary malignancies (MPMs) are a known phenomenon. We present a rare case of multicentric carcinoma of left breast synchronous with carcinoma of right lung. There was a diagnostic dilemma about the nature of the lung lesion, which otherwise would have been labeled as a metastasis from the breast primary; however, the immunohistochemistry markers distinguished between the two. The challenges in delivering radiotherapy in such not-so-conventional situations have been discussed. In spite of snag situation, patient can be treated safely with modern techniques and acceptable morbidities.